Ustekinumab biosimilar (Biocon)

乌司奴单抗生物类似药 (Biocon)

Report date: 2025/02/28 14:32:33

Base Information

Drug NameUstekinumab biosimilar (Biocon)
Drug Alias NameUstekinumab-kfceYesintekBmab 1200
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionInterleukin-12 inhibitorsInterleukin-23 inhibitorsInterleukin-12 subunit beta inhibitors
TargetsInterleukin-12Interleukin-23Interleukin-12 subunit beta
Therapy Area/IndicationsPlaque psoriasisPsoriasisCrohn Disease +[5] 
Global Approved IndicationsPsoriasisCrohn DiseaseColitis, Ulcerative +[4] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/11/29
Country/TerritoryUnited StatesIndiaEU +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBiocon Biologics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiocon Biologics IncBiosimilar Collaborations Ireland LtdBiocon Biologics Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisCrohn Disease +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A